Physician profile
Reba Isaac
NPI 1356348593
$14,557.78
in general payments reported to CMS, 2019-2025
27 companies · $2,398 in 2025
The $2,398 reported for 2025 was more than what 95% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,721 · 2020: $1,580 · 2021: $1,965 · 2022: $2,484 · 2023: $2,284 · 2024: $2,126 · 2025: $2,398.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,780 · Education: $28.12.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,779.77 |
| Education | $28.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $3,153.76 | 2019-2025 | Dovato, Cabenuva, Apretude |
| Gilead Sciences, INC. | $2,868.97 | 2019-2025 | Biktarvy |
| Merck Sharp & Dohme LLC | $1,520.02 | 2019-2025 | Pifeltro, Dificid, Delstrigo |
| Janssen Biotech, INC. | $997.54 | 2019-2025 | Symtuza, Stelara, Simponi |
| Theratechnologies INC. | $976.97 | 2019-2025 | Trogarzo, Egrifta |
| Abbvie INC. | $966.80 | 2019-2025 | |
| Insmed, INC. | $700.91 | 2019-2025 | Arikayce, Brinsupri |
| Paratek Pharmaceuticals, INC. | $574.09 | 2019-2025 | Nuzyra |
| La Jolla Pharmaceutical Company | $562.19 | 2020-2025 | Xerava, Zevtera, Giapreza |
| Melinta Therapeutics, LLC | $342.21 | 2020-2023 | Vabomere, Rezzayo |
| Shionogi INC | $289.77 | 2021-2025 | Fetroja |
| Takeda Pharmaceuticals U.S.A., INC. | $180.00 | 2022-2025 | Cuvitru |
| Janssen Products, LP | $178.99 | 2021-2022 | |
| Tetraphase Pharmaceuticals, INC. | $170.29 | 2020-2025 | |
| Baxter Healthcare | $157.88 | 2025 | Hillrom - Vest System Model 105 Home Care |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cumberland Pharmaceuticals, INC. | $146.66 | 2022-2025 | Vibativ |
| Allergan, INC. | $140.51 | 2019-2020 | |
| Emd Serono, INC. | $126.77 | 2019-2025 | |
| Mayne Pharma Commercial LLC | $107.51 | 2020-2022 | |
| Pfizer INC. | $104.91 | 2021-2024 | |
| Astellas Pharma US INC | $80.30 | 2024-2025 | Cresemba |
| Organogenesis INC. | $58.91 | 2020-2024 | Affinity |
| Nabriva Therapeutics, Plc | $57.16 | 2020-2021 | |
| Napo Pharmaceuticals INC | $36.46 | 2019 | |
| Redhill Biopharma INC. | $34.39 | 2020-2021 | |
| Janssen Scientific Affairs, LLC | $13.07 | 2020 | |
| Janssen Pharmaceuticals, INC | $10.74 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reba Isaac listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.